Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Sells $750,000.00 in Stock

Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Paul Bolno sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $15.00, for a total value of $750,000.00. Following the completion of the sale, the chief executive officer now owns 217,351 shares in the company, valued at $3,260,265. This represents a 18.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Paul Bolno also recently made the following trade(s):

• On Friday, November 15th, Paul Bolno sold 51,234 shares of Wave Life Sciences stock. The stock was sold at an average price of $14.32, for a total value of $733,670.88.
• On Wednesday, October 16th, Paul Bolno sold 90,474 shares of Wave Life Sciences stock. The shares were sold at an average price of $15.00, for a total value of $1,357,110.00.

Wave Life Sciences Stock Performance

NASDAQ:WVE opened at $15.10 on Friday. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -13.60 and a beta of -1.20. Wave Life Sciences Ltd. has a fifty-two week low of $3.50 and a fifty-two week high of $16.74. The stock has a fifty day moving average price of $12.49 and a 200-day moving average price of $8.13.

Analyst Ratings Changes

WVE has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research report on Wednesday, November 13th. Royal Bank of Canada raised their price objective on shares of Wave Life Sciences from $7.00 to $15.00 and gave the stock a “sector perform” rating in a research report on Monday, October 21st. B. Riley upped their target price on Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Raymond James raised Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $13.00 to $22.00 in a report on Wednesday, October 16th. Finally, JPMorgan Chase & Co. upped their price objective on Wave Life Sciences from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.22.

Institutional Investors Weigh In On Wave Life Sciences

Several institutional investors and hedge funds have recently bought and sold shares of WVE. ProShare Advisors LLC raised its position in Wave Life Sciences by 35.0% during the first quarter. ProShare Advisors LLC now owns 21,764 shares of the company’s stock valued at $134,000 after purchasing an additional 5,648 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Wave Life Sciences by 39.7% in the 1st quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company’s stock valued at $11,316,000 after purchasing an additional 521,665 shares during the last quarter. American International Group Inc. raised its holdings in shares of Wave Life Sciences by 23.3% during the 1st quarter. American International Group Inc. now owns 36,241 shares of the company’s stock worth $224,000 after buying an additional 6,851 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Wave Life Sciences by 14.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,861,254 shares of the company’s stock worth $11,485,000 after buying an additional 233,891 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Wave Life Sciences by 13.9% in the first quarter. Jacobs Levy Equity Management Inc. now owns 241,860 shares of the company’s stock valued at $1,492,000 after buying an additional 29,483 shares in the last quarter. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.